Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Kaplan-Meier Approach01:24

Kaplan-Meier Approach

98
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
98
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

97
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
97
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

120
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
120
Probability Laws01:49

Probability Laws

40.1K
Overview
40.1K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

12.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
12.4K
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

150
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
150

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Patient and Physician Global Disease Assessments in Systemic Sclerosis: Distinct and Complementary Constructs.

Arthritis care & research·2026
Same author

Does the ACR/EULAR Total Improvement Score Reflect How Individuals With Autoimmune Inflammatory Myopathies Feel and Function?

The Journal of rheumatology·2026
Same author

Distinct Systemic Sclerosis Phenotypes Related to Ethnicity: An Opportunity to Personalize Care?

Arthritis care & research·2026
Same author

Mouse models of immune-related adverse events: progress, challenges, and opportunities.

Trends in cancer·2026
Same author

Umbilical cord mesenchymal stromal cells for respiratory complications of COVID-19 infection (ProTrans): phase II randomized clinical trial.

Cytotherapy·2026
Same author

Discussion on ''Nonparanormal Adjusted Marginal Inference'' by Susanne Dandl and Torsten Hothorn.

Biometrics·2026

相关实验视频

Updated: Jun 6, 2025

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

10.9K

对罕见疾病的贝叶斯适应性可行性设计.

Maureen M Churipuy1, Shirin Golchi1, Marie Hudson2

  • 1Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, Québec, Canada.

Contemporary clinical trials communications
|December 2, 2024
PubMed
概括

本研究引入了贝叶斯设计,使用试点数据来预测临床试验样本大小可行性. 这种方法提高了效率,特别是在罕见疾病试验中.

关键词:
贝叶斯语 贝叶斯语 贝叶斯语 贝叶斯语临床试验临床试验是指临床试验的临床试验.可行性 可行性试点试验试验试验试验试验试验试验试验罕见疾病是一种罕见的疾病.招聘方式 招聘方式研究设计研究设计.

更多相关视频

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
00:06

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

13.6K
In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

20.6K

相关实验视频

Last Updated: Jun 6, 2025

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

10.9K
In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
00:06

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

13.6K
In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

20.6K

科学领域:

  • 临床试验 临床试验
  • 生物统计学 生物统计学
  • 贝叶斯的方法 贝叶斯的方法

背景情况:

  • 在研究开始之前,评估临床试验可行性,特别是样本大小的实现,至关重要.
  • 传统方法可能无法充分预测复杂试验的样本大小成功.

研究的目的:

  • 提出一个新的贝叶斯设计,用于预测临床试验样本大小可行性.
  • 为了证明这种设计在规划III期试验中的实用性,特别是对于罕见疾病.

主要方法:

  • 提出了一个贝叶斯框架,利用试点研究数据.
  • 一个基于玛-波桑分布的预测模型概述了估计目标样本大小.
  • 该设计使用模拟研究来说明在轻度系统性硬化症的III期试验的设计.

主要成果:

  • 建议的贝叶斯设计有效地预测了样本大小的可行性.
  • 玛-鱼分布模型为样本大小预测提供了一个强大的方法.
  • 预测性设计显示了提高罕见疾病临床试验效率的巨大潜力.

结论:

  • 提出的贝叶斯设计为改善临床试验规划和可行性评估提供了有价值的工具.
  • 这种方法可以导致更有效和成功的罕见疾病临床试验.
  • 准确的样本大小预测是优化资源配置和试验结果的关键.